OncoMatch/Clinical Trials/NCT03900793
Losartan + Sunitinib in Treatment of Osteosarcoma
Is NCT03900793 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Losartan and Sunitinib for osteosarcoma.
Treatment: Losartan · Sunitinib — This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Osteosarcoma
Performance status
ECOG OR KARNOFSKY 0–2
ECOG performance status (≥18 years old) ≤ 2 or Karnofsky performance score (<18 years old) ≥ 50
Demographics
Prior therapy
Lab requirements
Blood counts
Peripheral absolute neutrophil count (ANC) ≥ 750/mm3; Platelet count ≥ 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment); Hemoglobin ≥ 8 g/dL (with or without transfusion)
Kidney function
Creatinine clearance or radioisotope GFR > 70 mL/min/1.73 m2 OR a serum creatinine based on age/gender
Liver function
Total bilirubin ≤ 1.5 x ULN for age; SGPT (ALT) ≤ 135 U/L (ULN for SGPT is 45 U/L); Serum albumin ≥ 2.8 g/dL
Cardiac function
Current cardiac ejection fraction > 50% by biplane Simpson method on echocardiogram; QTc ≤ 480 ms
Adequate bone marrow function, defined as: Peripheral absolute neutrophil count (ANC) ≥ 750/mm3; Platelet count ≥ 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment); Hemoglobin ≥ 8 g/dL (with or without transfusion) Adequate renal function, defined as: Creatinine clearance or radioisotope GFR > 70 mL/min/1.73 m2 OR a serum creatinine based on age/gender. Adequate hepatic function, defined as: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age; SGPT (ALT) ≤ 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L; Serum albumin ≥ 2.8 g/dL Adequate cardiac function, defined as: Current cardiac ejection fraction > 50% by biplane Simpson method on echocardiogram; QTc ≤ 480 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital Los Angeles · Los Angeles, California
- Children's Hospital Colorado · Aurora, Colorado
- University of Colorado Hospital · Aurora, Colorado
- Children's Hospital of Atlanta · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03900793 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages